Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes

Dominick J. Angiolillo(University of Florida), Mark B. Effron(Eli Lilly (United States)), Andrew L. Frelinger(University of Nottingham), Jorge F. Saucedo, Clement K. Ojeh(Eli Lilly (United States)), Timothy M. Costigan(Eli Lilly (United States)), Paul A. Gurbel(Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Roger DeRaad(Black Hills Center for American Indian Health)
Journal of the American College of Cardiology
September 1, 2010
10.1016/j.jacc.2010.02.072
Cited by 168

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
|Circulation|2017|745
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651